Polymorphisms in genes involved in vincristine pharmacokinetics or pharmacodynamics are not related to impaired motor performance in children with leukemia

Leukemia Research

Volumn 34, Issue 2, 2010, Pages 154-159

  Hartman, A ^a   van Schaik, R H N ^b   van der Heiden, I P ^b   Broekhuis, M J C ^a   Meier, M ^a   den Boer, M L ^a   Pieters, R ^a  

^a SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Impaired motor performance; Leukemia; Polymorphisms

Indexed keywords

CYTOCHROME P450 3A5; MULTIDRUG RESISTANCE PROTEIN 1; TAU PROTEIN; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; AMINO ACID SUBSTITUTION; ARTICLE; CHILD; CHILDHOOD LEUKEMIA; CHROMOSOME 17; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG METABOLISM; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HAPLOTYPE; HUMAN; MALE; MOTOR PERFORMANCE; MUTATIONAL ANALYSIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PHARMACODYNAMICS; PHARMACOGENETICS; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

CHILD; CHILD, PRESCHOOL; CYTOCHROME P-450 CYP3A; DRUG RESISTANCE, NEOPLASM; FEMALE; GENOTYPE; HUMANS; MALE; P-GLYCOPROTEIN; PHARMACOGENETICS; POLYMORPHISM, GENETIC; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PSYCHOMOTOR PERFORMANCE; TAU PROTEINS; VINCRISTINE;

EID: 74849140695     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2009.04.027     Document Type: Article

References (32)

1. Harter S. The perceived competence scale for children. Child Dev 53 (1982) 87-97
2. Vainionpaa L. Clinical neurological findings of children with acute lymphoblastic leukaemia at diagnosis and during treatment. Eur J Pediatr 152 (1993) 115-119
3. Reinders-Messelink H., Schoemaker M., Goeken L., Van den Briel M., and Kamps W. Handwriting and fine motor problems after treatment for acute lymphoblastic leukemia. In: Simner M.L., Leedham C.G., and Thomassen A.J.W.M. (Eds). Handwriting and drawing research: basic and applied issues (1996), IOS Press, Amsterdam 215-225
4. Wright M.J., Halton J.M., Martin R.F., and Barr R.D. Long-term gross motor performance following treatment for acute lymphoblastic leukemia. Med Pediatr Oncol 31 (1998) 86-90
5. Gidding C.E., Kellie S.J., Kamps W.A., and de Graaf S.S. Vincristine revisited. Crit Rev Oncol Hematol 29 (1999) 267-287
6. Vainionpaa L., Kovala T., Tolonen U., and Lanning M. Vincristine therapy for children with acute lymphoblastic leukemia impairs conduction in the entire peripheral nerve. Pediatr Neurol 13 (1995) 314-318
7. Verstappen C.C., Koeppen S., Heimans J.J., Huijgens P.C., Scheulen M.E., Strumberg D., et al. Dose-related vincristine-induced peripheral neuropathy with unexpected off-therapy worsening. Neurology 64 (2005) 1076-1077
8. Hartman A., van den Bos C., Stijnen T., and Pieters R. Decrease in motor performance in children with cancer is independent of cumulative vincristine dose. Cancer 106 (2006) 1395-1401
9. Zhou-Pan X.R., Seree E., Zhou X.J., Placidi M., Maurel P., Barra Y., et al. Involvement of human liver cytochrome P450 3A in vinblastine metabolism: drug interactions. Cancer Res 53 (1993) 5121-5126
10. Van Schaik R.H., de Wildt S.N., Brosens R., van Fessem M., van den Anker J.N., and Lindemans J. The CYP3A4*3 allele: is it really rare?. Clin Chem 47 (2001) 1104-1106
11. Kuehl P., Zhang J., Lin Y., Lamba J., Assem M., Schuetz J., et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 27 (2001) 383-391
12. Hustert E., Haberl M., Burk O., Wolbold R., He Y.Q., Klein K., et al. The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics 11 (2001) 773-779
13. Dennison J.B., Jones D.R., Renbarger J.L., and Hall S.D. Effect of CYP3A5 expression on vincristine metabolism with human liver microsomes. J Pharmacol Exp Ther 321 (2007) 553-563
14. Song S., Suzuki H., Kawai R., and Sugiyama Y. Effect of PSC 833, a P-glycoprotein modulator, on the disposition of vincristine and digoxin in rats. Drug Metab Dispos 27 (1999) 689-694
15. Watanabe T., Miyauchi S., Sawada Y., Iga T., Hanano M., Inaba M., et al. Kinetic analysis of hepatobiliary transport of vincristine in perfused rat liver. Possible roles of P-glycoprotein in biliary excretion of vincristine. J Hepatol 16 (1992) 77-88
16. Hoffmeyer S., Burk O., von Richter O., Arnold H.P., Brockmoller J., Johne A., et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 97 (2000) 3473-3478
17. Chowbay B., Cumaraswamy S., Cheung Y.B., Zhou Q., and Lee E.J. Genetic polymorphisms in MDR1 and CYP3A4 genes in Asians and the influence of MDR1 haplotypes on cyclosporin disposition in heart transplant recipients. Pharmacogenetics 13 (2003) 89-95
18. Siegmund W., Ludwig K., Giessmann T., Dazert P., Schroeder E., Sperker B., et al. The effects of the human MDR1 genotype on the expression of duodenal P-glycoprotein and disposition of the probe drug talinolol. Clin Pharmacol Ther 72 (2002) 572-583
19. Johne A., Kopke K., Gerloff T., Mai I., Rietbrock S., Meisel C., et al. Modulation of steady-state kinetics of digoxin by haplotypes of the P-glycoprotein MDR1 gene. Clin Pharmacol Ther 72 (2002) 584-594
20. Plasschaert S.L., Groninger E., Boezen M., Kema I., de Vries E.G., Uges D., et al. Influence of functional polymorphisms of the MDR1 gene on vincristine pharmacokinetics in childhood acute lymphoblastic leukemia. Clin Pharmacol Ther 76 (2004) 220-229
21. Goto M., Masuda S., Saito H., Uemoto S., Kiuchi T., Tanaka K., et al. C3435T polymorphism in the MDR1 gene affects the enterocyte expression level of CYP3A4 rather than Pgp in recipients of living-donor liver transplantation. Pharmacogenetics 12 (2002) 451-457
22. Scott W.K., Nance M.A., Watts R.L., Hubble J.P., Koller W.C., Lyons K., et al. Complete genomic screen in Parkinson disease: evidence for multiple genes. JAMA 286 (2001) 2239-2244
23. Pastor P., Ezquerra M., Perez J.C., Chakraverty S., Norton J., Racette B.A., et al. Novel haplotypes in 17q21 are associated with progressive supranuclear palsy. Ann Neurol 56 (2004) 249-258
24. Tanahashi H., Asada T., and Tabira T. Association between tau polymorphism and male early-onset Alzheimer's disease. Neuroreport 15 (2004) 175-179
25. Veerman A.J., Hahlen K., Kamps W.A., Van Leeuwen E.F., De Vaan G.A., Solbu G., et al. High cure rate with a moderately intensive treatment regimen in non-high-risk childhood acute lymphoblastic leukemia. Results of protocol ALL VI from the Dutch Childhood Leukemia Study Group. J Clin Oncol 14 (1996) 911-918
26. Henderson S., and Sugden D. Movement assessment battery for children (1992), The Psychological Corporation, Sidcup, England
27. Smits-Engelsman B.C. Movement assessment battery for children; Nederlandse bewerking (1998), Swets & Zeitlinger, Lisse, Nederland
28. Croce R.V., Horvat M., and McCarthy E. Reliability and concurrent validity of the movement assessment battery for children. Percept Motor Skills 93 (2001) 275-280
29. Watanabe T., Suzuki H., Sawada Y., Naito M., Tsuruo T., Inaba M., et al. Induction of hepatic P-glycoprotein enhances biliary excretion of vincristine in rats. J Hepatol 23 (1995) 440-448
30. Saito T., Zhang Z.J., Shibamori Y., Ohtsubo T., Noda I., Yamamoto T., et al. P-glycoprotein expression in capillary endothelial cells of the 7th and 8th nerves of guinea pig in relation to blood-nerve barrier sites. Neurosci Lett 232 (1997) 41-44
31. Saito T., Zhang Z.J., Ohtsubo T., Noda I., Shibamori Y., Yamamoto T., et al. Homozygous disruption of the mdrla P-glycoprotein gene affects blood-nerve barrier function in mice administered with neurotoxic drugs. Acta Otolaryngol 121 (2001) 735-742
32. Goedert M. Neurofibrillary pathology of Alzheimer's disease and other tauopathies. Prog Brain Res 117 (1998) 287-306